FDA Announces Regulatory Review Period for LITFULO Patent Extension
May 10, 2025
May 10, 2025
WASHINGTON, May 10 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration (FDA) has determined the regulatory review period for the human drug product LITFULO (ritlecitinib tosylate), a treatment for severe alopecia areata in adults and adolescents aged 12 and older.
The decision was made following the submission of an application to the U.S. Patent and Trademark Office (USPTO) for a patent extension. This determination is in line with the requirem . . .
The decision was made following the submission of an application to the U.S. Patent and Trademark Office (USPTO) for a patent extension. This determination is in line with the requirem . . .